{
  "nctId": "NCT01573754",
  "briefTitle": "Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda",
  "officialTitle": "A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435",
  "protocolDocument": {
    "nctId": "NCT01573754",
    "filename": "Prot_SAP_ICF_000.pdf",
    "label": "Study Protocol, Statistical Analysis Plan, and Informed Consent Form",
    "date": "2020-02-25",
    "uploadDate": "2022-06-28T13:16",
    "size": 1152789,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01573754/document/Prot_SAP_ICF_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": true
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 48,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2006-03-21",
    "completionDate": "2021-07-06",
    "primaryCompletionDate": "2021-07-06",
    "firstSubmitDate": "2012-04-05",
    "firstPostDate": "2012-04-09"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Documented porphyria cutanea tarda (PCT)\n* Willing to give informed consent\n* Age 18 or greater\n\nExclusion Criteria:\n\n* Blistering skin lesions due to another condition",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "100 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Remission",
        "description": "Time to a decrease in plasma porphyrin concentration to less than 0.9 mcg/dL",
        "timeFrame": "To end of study, an average of 3 years"
      }
    ],
    "secondary": [
      {
        "measure": "50% Reduction in Plasma Porphyrin Level",
        "description": "50% reduction in plasma porphyrin level during treatment",
        "timeFrame": "To end of study, an average of 3 years"
      },
      {
        "measure": "75% Reduction in Plasma Porphyrin Level",
        "description": "Time to 75% reduction in plasma porphyrin level during treatment",
        "timeFrame": "To end of study, an average of 3 years"
      },
      {
        "measure": "Number of Days With Normal Urinary Porphyrin Levels",
        "description": "Number of days to normal urinary porphyrin levels for participants treated for Porphyria Cutanea Tarda (PCT). Days are summed together for all participants for a single value in each Arm.",
        "timeFrame": "To end of study, an average of 3 years"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:11.847Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}